Latest

Innovent's Q3 Product Revenue Climbs Over 40%; Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Rises 0.76% Intraday ] At 10:00 on Oct 29, 2026, Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) rose 0.76% to HK$14.550, turnover HK$58.65m, AUM HK$3.18bn, NAV HK$14.4312.
10:13
ETFChinaamc Hang Seng Hong Kong Biotech Index ETF03069.HK
Insurers' Potential Dividend Allocation Seen at About RMB 600 Billion; Ping An of China CSI HK Dividend ETF (03070.HK) Rises 1.92% Intraday ] At 9:57 on Oct 29, 2026, Ping An of China CSI HK Dividend ETF (03070.HK) rose 1.92% to HK$42.400 on turnover of HK$283,300, with AUM of HK$3.98 billion.
10:07
ETFPing An of China CSI HK Dividend ETF03070.HK
Hong Kong Q3 Earnings Season Nears Peak; Csop Hang Seng Tech Index Etf (03033.HK) Falls 1.59% Intraday ] At 9:55 on Oct 29, 2026, Csop Hang Seng Tech Index Etf (03033.HK) fell 1.59% to HK$3.722, turnover HK$1.38 billion, AUM HK$57.29 billion, NAV HK$3.7776.
10:02
ETFCSOP Hang Seng Tech Index ETF03033.HK
Samsung's Profit Miss Drags Korean Stocks Lower; Csop Ftse Hk-Korea Tech+ Index Etf (03431.HK) Falls 2.96% Intraday ] At 9:52 on Oct 29, 2026, Csop Ftse Hk-Korea Tech+ Index Etf (03431.HK) fell 2.96% to HK$8.685, turnover HK$2.68 million, AUM HK$1.02 billion, NAV HK$8.9799.
09:57
ETFCsop Ftse Hk-Korea Tech+ Index ETF03431.HK
EVERG SERVICES (06666.HK): Shares Suspended from 9 am Today ] On 29 Oct 2026, an HKEX notice said trading in EVERG SERVICES' (06666.HK) shares was suspended from 9 am that day, with no reason or resumption time given.
08:49
NewTimeSpaceEVERG SERVICES06666.HK
HUTCHMED (00013.HK): Sovleplenib Wins FDA Orphan Drug Status for Primary ITP ] On 29 Oct 2026, HUTCHMED (00013.HK) said sovleplenib won FDA orphan drug status for primary immune thrombocytopenia, with 7-year US exclusivity if approved.
08:15
NewTimeSpaceHUTCHMED00013.HK
WERIDE-W (00800.HK): Jingshuo Raises RMB70m and Adopts Incentive Plan; Stake Diluted to 67.63% ] On 29 Oct 2026, WERIDE-W (00800.HK) said investors will inject RMB70m into Jingshuo for 3.38%, with an incentive plan cutting its stake to about 67.63%.
08:01
NewTimeSpaceWERIDE-W00800.HK
ASCLETIS-B (01672.HK): ASC30 Meets Phase II Diabetes Endpoint with 1.7% HbA1c Reduction ] On 29 Oct 2026, ASCLETIS-B (01672.HK) said ASC30 cut HbA1c by a placebo-adjusted 1.7%, 1.6% and 1.7% at week 12 in a US Phase II diabetes trial.
07:41
NewTimeSpaceASCLETIS-B01672.HK
INNOVENT BIO (01801.HK): Q3 Product Revenue Exceeds RMB4.7bn, Up Over 40% ] On 29 Oct 2026, INNOVENT BIO (01801.HK) said Q3 product revenue exceeded RMB4.7bn, up over 40% year on year, driven by new products and TKI oncology drugs.
07:30
INNOVENT BIO01801.HKNewTimeSpace
BUD APAC (01876.HK): Nine-Month Revenue US$4.62bn, Normalised Profit US$628m ] On 29 Oct 2026, BUD APAC (01876.HK) posted nine-month revenue of US$4.62bn, down 3.7% organically, normalised EBITDA of US$1.25bn and normalised profit US$628m.
07:27
NewTimeSpaceBUD APAC01876.HK
DMALL (02586.HK): Completes Cloopen Acquisition with About 33.03% Effective Economic Interest ] On 29 Oct 2026, DMALL (02586.HK) completed its Cloopen acquisition, with the buyer drawing US$34.25m and holding effective economic interest of 33.03%.
07:20
NewTimeSpaceDMALL02586.HK
LEGENDHOLDING (03396.HK): Subsidiary Joyvio Food Q3 Revenue RMB276m, Up 30.3% ] On 29 Oct 2026, LEGENDHOLDING (03396.HK) said Joyvio Food posted Q3 revenue of RMB275.86m, up 30.34%, and net profit of RMB1.38m.
07:15
NewTimeSpaceLEGENDHOLDING03396.HK
MGM CHINA (02282.HK): Parent Reports Q3 Results; Macau Revenue Hits Quarterly Record ] On 29 Oct 2026, MGM CHINA (02282.HK) posted Q3 revenue of HK$8.93bn, up 4.9%, and adjusted EBITDA of HK$2.40bn, with record market share of 17.1%.
07:05
NewTimeSpaceMGM CHINA02282.HK
KING INTL INV (00928.HK) terminates rights issue after two substantial shareholders breach irrevocable undertakings ] KING INTL INV (00928.HK) terminated its rights issue after shareholders Wang Mengyao and Wei Yan failed to apply for any rights shares, breaching irrevocable undertakings.
23:17
KING INTL INV00928.HKrights issue
ALPHAMAB-B (09966.HK) JSKN033 doses first patient in Phase III cervical cancer study ] ALPHAMAB-B (09966.HK) said JSKN033, a subcutaneous ADC combination with a PD-L1 inhibitor, dosed its first patient in the Phase III JSKN033-301 cervical cancer study.
22:39
ALPHAMAB-B09966.HKClinical Trial
COSCO SHIP ENGY (01138.HK) chief accountant Tian Chao resigns, general manager to act as financial officer ] COSCO SHIP ENGY (01138.HK) said chief accountant Mr Tian Chao resigned on 28 October, with general manager Mr Wang Mingfeng to act as financial officer.
22:36
COSCO SHIP ENGY01138.HKresignation
HUAQIN (03296.HK) chairman Qiu Wensheng plans RMB10 million H share purchase from 29 October ] HUAQIN (03296.HK) said chairman Mr Qiu Wensheng plans to buy H shares with his own funds for RMB10 million between 29 October 2026 and 28 January 2027, with no price cap.
22:33
Huaqin03296.HKShare purchase
BRETON (01333.HK) signs strategic intent with Jinchengjian on DRC green energy and smart mining ] BRETON (01333.HK) signed a letter of intent with Jinchengjian on DRC green energy and smart mining, targeting 275MW of solar and 400MWh of storage and electric mining trucks.
22:30
BRETON01333.HKstrategic cooperation
GOLDSTONE CAP (01160.HK) probe finds executive director involved in potential insider trading, board to seek removal ] GOLDSTONE CAP (01160.HK) said a special committee found director Chen Changyi breached his duties and was involved in potential insider trading, recommending removal.
22:28
GOLDSTONE CAP01160.HKDisciplinary Action
YANKUANG ENERGY (01171.HK) issues RMB2 billion of 3+N-year M&A MTNs at 1.67%, proceeds received 26 October ] YANKUANG ENERGY (01171.HK) issued RMB2 billion of 2026 third-tranche MTNs (M&A) on 23 October at a 1.67% coupon, with a 3+N year term; proceeds were received on 26 October.
21:35
YANKUANG ENERGY01171.HKmedium-term notes
Previous1..34 567..604     604 pages total
×
Share to WeChat

Open WeChat, use "Scan," and share to my Moments